변실금 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2025-2030년)

According to Mordor Intelligence, the fecal incontinence market size stands at USD 3.41 billion in 2025 and is projected to reach USD 4.38 billion by 2030, registering a 5.11% CAGR over the forecast period.

This report is Segmented by Product (Pads & Liners, Bowel Management Systems, Anal Plugs, Bulking Agents, Sacral Nerve Stimulation Implants, Biofeedback Equipment), Patient Type (Adult, Paediatric), End User (Hospitals, Ambulatory Surgical Centres, Home-Care Settings, Long-Term Care Facilities), and Geography. The Market Forecasts are Provided in Terms of Value (USD), Based On Availability.

Global Fecal Incontinence Market Trends and Insights

Rapidly aging global population

Adults aged 65 and older exhibit a 15% fecal-incontinence prevalence compared with 8% among all adults, expanding the addressable base as longevity rises. Annual economic burden per patient averages USD 4,110, split between direct care costs and productivity losses, escalating pressure on payers. Nursing-home prevalence of 50-70% drives institutional demand for advanced bowel-management systems. Age-related comorbidities such as diabetes and neurological disorders further elevate risk. Long-term care providers increasingly view advanced containment and neuromodulation solutions as cost-effective given the staffing efficiencies they create. Consequently, the fecal incontinence market is tightly coupled to aging trends in high-income economies.

Rising prevalence of chronic GI disorders

Inflammatory bowel disease patients report 54% fecal-incontinence incidence, far exceeding population baselines and underscoring unmet therapeutic needs. Irritable bowel syndrome carries a 52% lifetime incidence, amplifying demand for structured management pathways. Psychological distress linked to uncontrolled symptoms accelerates help-seeking behavior, with 56% of respondents in recent surveys prioritizing fatigue and continence control. Post-surgical complications, especially after rectal-cancer resections, introduce additional patient pools that require devices such as transanal irrigation kits and neuromodulation implants. Together these factors sustain double-digit growth pockets within the broader fecal incontinence market.

Social stigma and under-reporting

Only 23% of patients accurately disclose fecal-incontinence episodes during clinical encounters, highlighting a substantial recognition gap. Cultural norms frame the condition as an inevitable result of aging or childbirth, discouraging proactive care seeking. Clinicians seldom initiate dialogue, missing early intervention windows. Advocacy groups and peer-support platforms have begun public-awareness campaigns, yet behavior change remains gradual. Digital therapeutics that allow discreet home treatment lessen embarrassment, but stigma continues to constrain the fecal incontinence market.

Other drivers and restraints analyzed in the detailed report include:

1. Growing adoption of minimally-invasive bowel-management devices
2. Favorable reimbursement for sacral neuromodulation
3. High cost of advanced implants and procedures

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Pads and liners generated the largest revenue slice, holding 37.42% of the fecal incontinence market in 2024. Device familiarity, wide retail distribution, and immediate symptom containment sustain their prominence. In contrast, sacral-nerve-stimulation implants are the fastest-growing category, advancing at a 9.31% CAGR as payers widen coverage and clinical data consolidate their superiority in durable continence restoration. The fecal incontinence market size for neuromodulation products is set to widen further as manufacturers introduce MRI-safe generators and longer-lasting batteries. Emerging bowel-management systems that integrate sensors with closed drainage have cut nursing time by 59%, improving hospital efficiency. Biofeedback equipment is enjoying a digital renaissance, with cloud-linked platforms enabling remote coaching and adherence tracking. Bulking agents remain confined by regulatory complexity, whereas anal plugs serve niche postoperative applications.

Demand for advanced products is being catalyzed by the Boston Scientific-Axonics merger, which consolidates IP portfolios, enhances distribution reach, and funds pipeline expansions. Competitive differentiation now revolves around device miniaturization, battery longevity, and software ecosystems that capture real-world evidence. Taken together, these dynamics reinforce neuromodulation as the innovation engine within the fecal incontinence market.

Complete Report Scope:

• By Product
  • Pads & Liners
  • Bowel Management Systems
  • Anal Plugs
  • Bulking Agents
  • Sacral Nerve Stimulation Implants
  • Biofeedback Equipment
• By Patient Type
  • Adult
  • Paediatric
• By End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Home-care Settings
  • Long-term Care Facilities
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained a 41.23% fecal incontinence market share in 2024, supported by mature reimbursement systems, high procedure volumes, and ongoing NIH-funded neuromodulation research. Payer pilots such as Mass General Brigham Health Plan's pelvic-health initiative bundle sensor-enabled products with virtual coaching, enhancing patient engagement and reducing downstream costs.

Europe represents a mature and highly structured landscape. Germany, the United Kingdom, and France spearhead adoption through specialized pelvic-floor rehabilitation centers and coordinated care networks. Harmonized EU regulatory pathways expedite device approvals, although pricing pressures encourage adoption of cost-effectiveness frameworks. Multicenter clinical trials evaluating transanal irrigation for low anterior resection syndrome continue to fine-tune patient-selection criteria, supporting sustainable growth across the region.

Asia-Pacific is the fastest-growing territory, expanding at 7.63% CAGR on the back of rising health-care expenditure and improved awareness campaigns. Cross-sectional surveys in China reveal elevated pelvic-floor dysfunction prevalence coupled with limited public literacy, highlighting education as a key growth lever. Thailand's urogynecology associations are scaling professional-training programs that integrate Western and traditional modalities, enlarging the physician talent pool. Japan's super-aged demographic and robust insurance coverage underpin early adoption of premium devices, while emerging economies leverage medical tourism to access advanced treatments. These developments collectively diversify revenue streams and amplify the global fecal incontinence market.

1. Axonics Inc.
2. B. Braun
3. Boston Scientific
4. Coloplast
5. Consure Medical
6. ConvaTec Group plc
7. Dentsply Sirona
8. Hollister
9. Laborie
10. Laborie Medical Technologies
11. Medtronic
12. Renew Medical Inc.
13. Solventum
14. SRS Medical
15. Teleflex
16. TG Eakin Ltd
17. Zyno Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapidly Aging Global Population
  • 4.2.2 Rising Prevalence Of Chronic GI Disorders
  • 4.2.3 Growing Adoption Of Minimally-Invasive Bowel Management Devices
  • 4.2.4 Favourable Reimbursement For Sacral Neuromodulation
  • 4.2.5 AI-Enabled Biofeedback Therapy Platforms
  • 4.2.6 Expansion Of Pelvic-Floor Neuromodulation Clinics In Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 Social Stigma & Under-Reporting Of The Condition
  • 4.3.2 High Cost Of Advanced Implants & Procedures
  • 4.3.3 Fragmented Regulatory Pathways For Bio-Absorbable Bulking Agents
  • 4.3.4 Shortage Of Colorectal Specialists Trained In Latest Therapies
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Product
  • 5.1.1 Pads & Liners
  • 5.1.2 Bowel Management Systems
  • 5.1.3 Anal Plugs
  • 5.1.4 Bulking Agents
  • 5.1.5 Sacral Nerve Stimulation Implants
  • 5.1.6 Biofeedback Equipment
• 5.2 By Patient Type
  • 5.2.1 Adult
  • 5.2.2 Paediatric
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centres
  • 5.3.3 Home-care Settings
  • 5.3.4 Long-term Care Facilities
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Axonics Inc.
  • 6.3.2 B. Braun Melsungen AG
  • 6.3.3 Boston Scientific Corp.
  • 6.3.4 Coloplast A/S
  • 6.3.5 Consure Medical
  • 6.3.6 ConvaTec Group plc
  • 6.3.7 Dentsply Sirona
  • 6.3.8 Hollister Inc.
  • 6.3.9 Laborie
  • 6.3.10 Laborie Medical Technologies
  • 6.3.11 Medtronic plc
  • 6.3.12 Renew Medical Inc.
  • 6.3.13 Solventum
  • 6.3.14 SRS Medical
  • 6.3.15 Teleflex Inc.
  • 6.3.16 TG Eakin Ltd
  • 6.3.17 Zyno Medical

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment